First annual report of the Austrian CML registry (Q42862831)

8 November 2017

title

First annual report of the Austrian CML registry (English)

1 reference

8 November 2017

Stefan Schmidt

1

1 reference

8 November 2017

Dominik Wolf

2

1 reference

8 November 2017

Josef Thaler

3

1 reference

8 November 2017

Sonja Burgstaller

4

1 reference

8 November 2017

Wolfgang Linkesch

5

1 reference

8 November 2017

Andreas Petzer

6

1 reference

8 November 2017

Michael Fridrik

7

1 reference

8 November 2017

Alois Lang

8

1 reference

8 November 2017

Hermine Agis

9

1 reference

8 November 2017

Peter Valent

10

1 reference

8 November 2017

Otto Krieger

11

1 reference

8 November 2017

Alois Walder

12

1 reference

8 November 2017

Markus Korger

13

1 reference

8 November 2017

Ernst Schlögl

14

1 reference

8 November 2017

Tamer Sliwa

15

1 reference

8 November 2017

Ernst Wöll

16

1 reference

8 November 2017

Manfred Mitterer

17

1 reference

8 November 2017

Wolfgang Eisterer

18

1 reference

8 November 2017

Michael Pober

19

1 reference

8 November 2017

Günther Gastl

20

1 reference

8 November 2017

ASHO CML registry

21

1 reference

8 November 2017

publication date

11 October 2010

1 reference

8 November 2017

published in

Vienna Clinical Weekly

1 reference

8 November 2017

volume

122

1 reference

8 November 2017

issue

19-20

1 reference

8 November 2017

page(s)

558-566

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-010-1450-X

Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20936366

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00508-010-1450-X

1 reference

8 November 2017

1 reference